Relacorilant
- Generic Name
- Relacorilant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22F4N6O3S
- CAS Number
- 1496510-51-0
- Unique Ingredient Identifier
- 2158753C7E
- Background
Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).
- Associated Conditions
- -
- Associated Therapies
- -
CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 130
- Registration Number
- NCT03508635
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom
Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT03457597
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 35
- Registration Number
- NCT02804750
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath